An observational study in Bronchiolitis, Viral, sponsored by Centre Hospitalier Intercommunal Creteil. Completed at 5 sites in France. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Centre Hospitalier Intercommunal Creteil · Observational
Respiratory tract infections caused by respiratory syncytial virus (RSV) are a worldwide burden and represent a major public health issue. In France, bronchiolitis is responsible for around 100,000 emergency room visits and 50,000 hospital admissions every year; 75% of infants hospitalised for RSV bronchiolitis are healthy full-term children.
Recent discoveries concerning the specific viral epitopes of RSV have made it possible to move from an empirical approach to a targeted preventive or curative approach (monoclonal antibodies, vaccines, anti-viral drugs).
Nirsevimab is a monoclonal antibody against RSV with enhanced neutralising activity and a prolonged half-life. A randomised, placebo-controlled phase III trial demonstrated the effectiveness of nirsevimab in reducing lower respiratory tract infections caused by RSV requiring medical management in healthy premature and term infants, with a favourable safety profile. The US Food and Drug Administration (FDA) approved the first RSV vaccine on May 3, 2023, and the second was approved on May 31, 2023. Nirsevimab was approved by the European Medicines Agency (EMA) on November 4, 2022.
30 studies on the registry are indexed under Bronchiolitis, Viral; 2 are open to participants now.
Browse Bronchiolitis, Viral studies →Centre Hospitalier Intercommunal Creteil is the lead sponsor of 131 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Paediatric patients under 12 months of age treated for RSV bronchiolitis (for cases), or for one of the conditions listed in the inclusion criteria (for controls).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cases :
Controls :
Exclusion Criteria:
Collection of medical data in a non-identifying way (demographic data, medical history, clinical data, microbiological data) to meet the objectives of the research.
Other: No intervention required by the protocol
Collection of medical data in a non-identifying way (demographic data, medical history, clinical data, microbiological data) to meet the objectives of the research.
Other: No intervention required by the protocol
No visits or samples will be taken specifically for this study. This research involves only prospective or retrospective data collection in relation to the usual hospital management of the child included. Similarly, patient follow-up will be strictly within the framework of their usual hospital care in relation to their pathology.
Proportion of patients passively immunised with nirsevimab
Proportion of patients passively immunised with nirsevimab in children hospitalised with RSV bronchiolitis and in the control group
Time frame: 7 days
Proportion of hospitalised children for RSV bronchiolitis requiring invasive or non-invasive ventilatory passively immunised with nirsevimab
Proportion of children passively immunised with nirsevimab hospitalised for bronchiolitis requiring invasive or non-invasive ventilatory support, including RSV bronchiolitis
Time frame: 7 days
Length of hospital stay
Length of hospital stay for children with RSV bronchiolitis.
Time frame: 7 days
Time immunisation
Time between immunisation with nirsevimab and hospitalisation for RSV bronchiolitis.
Time frame: 7 days
Frequency of hospital admissions
Monthly frequency of hospital admissions for RSV bronchiolitis among participating centres over time
Time frame: 7 days
Proportion of children hospitalised for RSV bronchiolitis with viral co-detection
Proportion of children hospitalised for RSV bronchiolitis with viral co-detection or viral detection other than RSV on nasopharyngeal swab
Time frame: 7 days
Plan to share: No
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Intercommunal Creteil →